Qtrex Quantum Ltd. · NASDAQ:QTEX
Qtrex Quantum — Inspira Technologies — Investor Presentation (March 2026)
16 slides from Qtrex Quantum's investor presentation, March 2026
Slide 1: Inspira Technologies Investor Presentation March 2026
Inspira Technologies Nasdaq: IINN Investor Presentation MARCH 2026 Copyright © 2018-2026 Inspira-Technologies OXY B.H.N. LTD., All rights reserved. See Disclaimers on slides 2-3 1
Slide 2: Forward Looking Statement Disclaimer
Forward Looking Statement Disclaimer This presentation contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward- looking statements and their implications are based on the current expectations of the management of Inspira Technologies OXY B.H.N..
Slide 3: Disclaimers
Disclaimers Mechanical Ventilation refers to Invasive Mechanical Ventilation. Planned timelines, milestones, estimates or assumptions are subject to change. The INSPIRA ART100 system has FDA 510(k) clearance and Israeli AMAR certification for Cardiopulmonary Bypass and ECMO procedures. The INSPIR
Slide 4: Mission Statement
Mission Statement To provide acute respiratory care patients a minimally invasive respiratory support solution, which may eliminate the need for mechanical ventilators, intubation and induced coma. Copyright © 2018-2026 Inspira-Technologies OXY B.H.N. LTD., All rights reserved. See Disclaimers on sl
Slide 5: Mechanical Ventilation: The Human and Economic Cost
Mechanical Ventilation: The Human and Economic Cost $19B 20M Market Opportunity¹ Patient Volume² Market for the legacy standard of Patients placed on invasive care. mechanical ventilation annually. >50% Mortality Associated with Legacy Procedures³. Significant risks include lung injury, infections a
Slide 6: A Critical Gap
Early Stage Last Resort A Critical Gap No intermediate solution to treat failing lungs - the market is split between two distinct extremes, with no middle ground. Non-Invasive Basic Oxygen Therapy Invasive Mechanical Ventilation Early Stage: Safe and comfortable, but insufficient for Last Resort: Po
Slide 7: New Treatment Paradigm
New Treatment Paradigm Bridging the treatment gap between non-invasive and invasive respiratory support INSPIRATM ART500 SYSTEM NON-INVASIVE VENTILATION: Nasal plugs, face mask, HFNC, BIPAP/CPAP, oxygen helmet. INSPIRATM ART500 SYSTEM Awake extracorporeal respiratory support INVASIVE MECHANICAL VENT
Slide 8: INSPIRA ART500
NEXT-GENERATION RESPIRATORY SUPPORT INSPIRA ART500 Designed to elevate and stabilize declining oxygen saturation levels without mechanical ventilation. Rapid Response Rapidly boosts oxygen saturation levels within minutes - potentially enabling treatment of a great number of patients, both in and be
Slide 9: Core Technology
Core Technology: 01 INSPIRA ART500: NEXT-GENERATION RESPIRATORY SUPPORT Smart Console: Intuitive interface designed for general ICU staffs. AI algorithms analyze sensor data and provide clear decision-support guidance. 02 Real-Time Blood Sensor: Current intermittent blood tests leave hours-long "gap
Slide 10: Inspira Technologies: The Generational Leap
Inspira Technologies: The Generational Leap GEN 1: INSPIRA ART100 GEN 2: INSPIRA ART500 FDA 510(K) CLEARED P R O V E N F I E L D - T E S T E D T E C H N O L O G Y IN DEVELOPMENT Function: Blood Oxygenation Function: Adaptive Blood Oxygenation Use Cases: Cardiopulmonary Bypass and ECMO Use Cases: Ear
Slide 11: INSPIRA ART100
INSPIRA ART100 Proven Track Record FDA Cleared 510(k) cleared for short-duration cardiopulmonary bypass procedures. Deployed Incorporated into routine hospital workflow at top-ranked U.S. academic medical center. $49.5M in Binding Purchase Orders (Outside the U.S.) Designed for healthcare systems fa
Slide 12: HYLA: Clip-On Blood Monitoring System
HYLA : Clip-On Blood Monitoring System Continuous & Contactless Real-Time Data Second-by-second monitoring of key blood parameters replaces intermittent lab tests. Non-Invasive Optical sensor technology means zero blood contact or loss, critical for long-term care. Device Agnostic Clips onto the tub
Slide 13: Market Momentum
Market Momentum Permanent Preparedness Post-COVID healthcare systems maintain respiratory surge readiness. The Training Barrier Has Collapsed ICU teams now have hands-on experience with extracorporeal support. Expanding U.S. Market Indications Use cases expanding into lung transplant and organ prese
Slide 14: Intellectual Property
Intellectual Property Extracorporeal Oxygenation System A Cannula Fixation Device For low flow rates and methods of use. Secures a neck cannula from moving Two U.S. patents granted. or dislodging. Filed in Canada, Europe, China, Korea, Japan, Patent granted in Israel Australia, Brazil and Israel Fil
Slide 15: Roadmap to Market Disruption
Inspira Technologies Roadmap to Market Disruption FDA 510(k) Submission Blood Pump INSPIRA ART500 Gen.1 Development Freeze FDA 510(k) Aims to FDA 510(k) Clearance Replace Submission FDA 510(k) HYLA Gen.1 Clearance HYLA Gen.2 Mechanical FDA listing HYLA Gen.1 Ventilators INSPIRA ART100 CART Blood Pum
Slide 16: Board & Management
Board & Management Lior Amit Tal Parnes Sivan Matza Director Chairman Director Veteran finance Serial entrepreneur, Senior investment executive with extensive veteran executive executive in global corporate finance in the medical capital markets experience technology industry Dagi Ben-Noon, BSc Avi
Inspira Technologies — Investor Presentation (March 2026) on 6ix